EUCTR2007-001585-33-ES进行中（未招募）不适用
Estudio clínico multicéntrico, aleatorizado y controlado con placebo para investigar la eficacia de rituximab (MabThera/Rituxan) en la inhibición del daño estructural articular valorado por resonancia magnética nuclear en pacientes con artritis reumatoide y una respuesta inadecuada al metotrexato - estudio SCORE. - SCORE
F. Hoffman-La Roche Ltd.0 个研究点目标入组 180 人开始时间: 2007年9月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Able and willing to give written informed consent and comply with the requirements of the study protocol
- •2.Patients with active RA for at least 3 months diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of RA
- •3.Disease duration = 10 years
- •4.Either anti-cyclic citrullinated peptide (anti-CCP) (= 20 Units) or rheumatoid factor positive (=20 IU/mL) or both
- •5.Active disease as defined by DAS28-CRP = 3.2
- •6.Evidence of erosive disease and/or clinical synovitis in a signal (MRI) joint (metacarpophalangeal and/or wrist)
- •RA duration > 1 year: at least one erosion evaluated by a radiograph at the X-ray screening visit and evidence of clinical synovitis
- •RA duration = 1 year: evidence of clinical synovitis*
- •7.Age = 18 and = 80 years
- •8.Glucocorticoids =10 mg/day prednisolone or equivalent permitted if stable for at least 4 weeks prior to baseline
- •9.Use of non-steroidal anti inflammatory drugs is permitted if stable for at least 4 weeks prior to baseline
- •10.For patients of reproductive potential (males and females), use of a reliable means of contraception (e.g., hormonal contraceptive, patch, intrauterine device, physical barrier) throughout study participation
- •11.Experiencing inadequate response to MTX at a dose of 12.5 25 mg/week (p.o. or parenteral) for at least 12 weeks, with the last 4 weeks prior to baseline maintained at a stable dose. Minimal MTX doses of 7.5 or 10 mg/week are permitted only in case of documented intolerance to higher doses.
- •*In the event that clinical synovitis is not confirmed by MRI assessment at baseline, the patient will be excluded from the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria related to RA:
- •1.Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis or Felty’s syndrome). Secondary Sjögren’s syndrome or secondary limited cutaneous vasculitis with RA is permitted
- •2.Bed-bound or wheelchair bound patients
- •3.History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or any overlap syndrome)
- •4.Diagnosis of juvenile idiopathic arthritis, also known as juvenile RA and/or RA before age 16.
- •Exclusion criteria related to general health:
- •1.Any surgical procedure, including bone/joint surgery/synovectomy (including joint fusion or replacement) within 12 weeks prior to baseline or planned within 24 weeks of randomization
- •2.Lack of peripheral venous access
- •3.Pregnancy or breast feeding
- •4.Significant cardiac or pulmonary disease, including obstructive pulmonary disease
- •5.Evidence of significant, uncontrolled, concomitant disease such as, but not limited to, nervous system, renal, hepatic, endocrine, or gastrointestinal disorders which, in the investigator’s opinion, would preclude patient participation
- •6.Primary or secondary immunodeficiency (history of, or currently active), including known history of HIV infection
- •7.Known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with i.v. anti infectives within 4 weeks prior to baseline or completion of oral anti-infectives within 2 weeks prior to baseline
- •8.History of deep space/tissue infection (e.g., fasciitis, abscess, osteomyelitis) within 52 weeks prior to baseline
- •9.History of serious recurrent or chronic infection (patients will be screened for chest infections using a chest radiograph at screening if not previously performed within the 12 weeks prior to screening)
- •10.History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ (except basal cell or squamous cell carcinoma of the skin that has been excised and cured)
- •11.Any neurological (congenital or acquired), vascular or systemic disorder which could affect any of the efficacy assessments, in particular, joint pain and swelling (e.g., Parkinson’s disease, cerebral palsy, diabetic neuropathy)
- •12.Currently active alcohol or drug abuse or history of alcohol or drug abuse within 24 weeks prior to baseline.
- •Exclusion criteria related to medications:
- •1.History of a severe allergic or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of rituximab or to murine proteins
- •2.Previous treatment with any approved or investigational biologic agent for RA
- •3.Previous treatment with an anti-alpha 4 integrin antibody or co stimulation modulator
- •4.Previous treatment with any B cell modulating or cell depleting therapies, including investigational agents (e.g., CAMPATH, anti CD4, anti-CD5, anti CD3, anti CD19, anti-CD11a, anti-CD22, anti BLys/BAFF, and anti-CD20)
- •5.Treatment with any investigational agent within 28 days of baseline or five half lives of the investigational drug (whichever is the longer)
- •6.Receipt of any vaccine within 28 days prior to baseline. It is
研究者
相似试验
进行中（未招募）
1 期
Estudio clínico multicéntrico, aleatorizado y abierto, con cuatro ramas de tratamiento para investigar la dosis óptima de una pauta inmunosupresora basada en Prograf® / Advagraf® en pacientes trasplantados renales. Protocolo del estudio fase IIIb de Advagraf® (FK506E (MR4)) - Título corto: OSAKA StudyProphylaxis of rejection in kidney allograft recipients (via immunosuppression)Profilaxis del rechazo en pacientes receptores de un injerto renalMedDRA version: 9.1Level: LLTClassification code 10023438Term: Kidney transplantEUCTR2007-005376-13-ESAstellas Pharma Europe Ltd.1,200
进行中（未招募）
1 期
Estudio clínico multicéntrico, aleatorizado, comparativo, de distintos regímenes de administración de deferasirox en la tolerabilidad gastrointestinal (GI), en pacientes con síndrome mielodisplásico (SMD) de riesgo bajo o intermedio (int-1) con sobrecarga de hierro transfusionalEUCTR2011-001077-13-ESovartis Farmacéutica S.A.
进行中（未招募）
1 期
Ensayo clínico multicéntrico, aleatorizado y controlado con placebo para evaluar la eficacia de la utilización perioperatoria de ácido tranexámico sobre la hemorragia quirúrgica en la cirugía compleja de columna.Clinical trial, multicenter, randomized and placebo controlled to evaluate the efficacy of the peri-operative use of tranexamic acid on surgical bleeding in major spinal surgeryPrevención antihemorrágica en cirugia compleja de columnaAntihemorragic prevention major spinal surgeryMedDRA version: 9.1Level: PTClassification code 10041564Term: Spinal deformity correctionMedDRA version: 9.1Level: HLTClassification code 10041544Term: Spinal cord and nerve root disorders NECMedDRA version: 11Level: PTClassification code 10065667Term: Profilaxis antihemorrágicaEUCTR2008-006938-94-ESDra Maria José Colomina Soler130
进行中（未招募）
不适用
Ensayo clínico, multicéntrico, aleatorizado, controlado y doble ciego, para el estudio de la terapia puente con bemiparina sódica frente a heparina cálcica no fraccionada en procedimientos invasivos ambulatorios, en cirugía ambulatoria y en cirugía general laparoscópica en pacientes bajo tratamiento con anticoagulante oral - BERTAPrevención de la enfermedad tromboembólica en pacientes sometidos a cirurgía general con riesgo moderado o a cirurgía ortopédica. Profilaxis de la trombosis venosa profunda en pacientes no quirúrgicos con riesgo elevado o moderado.EUCTR2006-001862-17-ESInstitut de Recerca de l'Hospital de la Santa Creu i Sant Pau
进行中（未招募）
不适用
Ensayo clínico multicéntrico, aleatorizado, controlado para evaluar la eficacia del tratamiento con carbonato de litio en pacientes con Esclerosis Lateral AmiotróficaEsclerosis Lateral AmiotróficaMedDRA version: 9Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisEUCTR2008-006224-61-ESInstitut de Recerca de l'Hospital de la Santa Creu i Sant Pau